{
  "docId": "019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "docSlug": "5062b9a9257606648ea145bccd66e04d",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 41 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 41,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Slide 12 of the deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b7ca-70fb-95b8-5a74e3aefffe/12",
  "deckHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe",
  "deckJsonHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe.json",
  "deckAnchorHref": "/decks/019de076-b7ca-70fb-95b8-5a74e3aefffe#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.875,
        "w": 0.286,
        "x": 0.714,
        "y": 0
      },
      "kind": "callout",
      "text": "AT-A-GLANCE\n\nMechanism of Action:\nALK-selective tyrosine kinase inhibitor\n\nStage of Development:\nGlobal Phase 1\n\nInitial Development Indication:\nALK-positive NSCLC\n\nFDA Designations:\nOrphan Drug Designation",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c0b1b43-a649-4f02-910d-0b2334157863",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.08,
        "y": 0.59
      },
      "kind": "subtitle",
      "text": "A brain-penetrant, selective inhibitor of ALK and ALK resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddc7695d-e972-45db-add9-336e70aa0ec0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.39,
        "x": 0.08,
        "y": 0.395
      },
      "kind": "title",
      "text": "NVL-655 for ALK+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a895722e-4624-4d95-80e0-0c17a732f3a4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "f9b08a01-e32c-4f66-9cfd-36fd8c059333",
      "evidence": "AT-A-GLANCE",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 12,
      "beatId": "b1774785-2429-4d83-9f6f-95b57f9114be",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents the product details for Nuvalent's therapies, including NVL-655 and NVL-520.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 12,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "2ad14173-59a5-409e-9eff-4f8d228ecb07",
      "evidence": "The document presents a detailed breakdown of Nuvalent's therapies, including their innovative approach and promising clinical trial results.",
      "position": 1,
      "objective": "How do Nuvalent's therapies address the needs of patients with cancer?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}